OncoNano Medicine, Inc. is a biotechnology company based in Southlake, Texas, specializing in the development of innovative products for the diagnosis and treatment of cancer. Their cutting-edge technology utilizes ultra pH-sensitive polymeric micelles to encapsulate and selectively release therapeutic and imaging payloads in acidic tumor microenvironments, enabling targeted delivery while minimizing exposure to normal tissues. With a focus on exploiting universal tumor and immune targets, OncoNano Medicine aims to provide patients with a range of solutions, including solid tumor therapeutics, real-time image-guided surgery agents, and T cell activating immunotherapies.
Through their proprietary micelle technology, OncoNano Medicine has achieved threshold pH sensing and activation of Stimulator of Interferon Genes (STING), a crucial immune signaling molecule for T cell therapy of solid tumors. This unique approach allows for high specificity in tumor targeting and has shown promising results in preclinical studies and in patients. With a well-funded company and strategic partnerships, OncoNano Medicine is at the forefront of advancing cancer identification and treatment, making meaningful impacts across the continuum of patient care.
Generated from the website